aTyr Pharma reports Q2 EPS (22c), consensus (28c)

Reports Q2 cash, restricted cash, cash equivalents and investments as of June 30 were $112M. Based on the Company’s current operational plans and existing cash, the Company maintains its prior guidance and believes its cash runway will extend into 2026…”Throughout the second quarter we have continued to progress and invest in our clinical development program for our lead therapeutic candidate, efzofitimod, in interstitial lung disease (ILD),” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Our global pivotal Phase 3 EFZO-FIT(TM) study in patients with pulmonary sarcoidosis, the most prevalent form of ILD, continues to enroll and our Phase 2 EFZO-CONNECT study in patients with systemic sclerosis associated ILD , is expected to enroll the first patient in the third quarter.”